{'fraction_non_alphanumeric': 0.015212981744421906, 'fraction_numerical': 0.005070993914807302, 'mean_word_length': 5.854166666666667, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Is there clinical value to sentinel lymph node sampling in colon cancer?

The well-established concept of sentinel lymph node (SLN) sampling for malignancies is based on the orderly and sequential flowoflymphaticfluidfromthesiteoftheprimarytumorthrough the lymphatic vessels and lymph nodes within the draining lymphatic basin. It is accepted that the lymphatic dissemination of tumor cells follows this pattern, with the additional supposition that the tumor cells will be effectively filtered out in the lymph nodes in the drainage basin. When this concept applies, localization, removal, and pathologic analysis of SLNs provides important staging and prognostic information regarding lymphatic dissemination of the primary tumor. The accuracy and advantages of SLN sampling for malignancies of the integumentary system (principally melanoma and breast cancer) have been well documented in multiple trials since Morton’s original report on SLN biopsy for malignant melanoma in 1992. 1